Talphera, Inc. engages in the development and commercialization of therapies used in medically supervised settings. The company is headquartered in San Mateo, California and currently employs 13 full-time employees. The company went IPO on 2011-02-11. The Company’s portfolio consists of nafamostat product candidates and pre-filled syringe product candidates. The Company’s lead product candidate, Niyad, is a lyophilized formulation of nafamostat and is being studied under an investigational device exemption (IDE) as an anticoagulant for the extracorporeal circuit. Niyad is used in adult patients undergoing continuous renal replacement therapy (CRRT). LTX-608 is its nafamostat formulation for direct IV infusion being explored as an investigational product for one or more indications, including antiviral treatment, or treatment of acute respiratory distress syndrome (ARDS) disseminated intravascular coagulation (DIC), or acute pancreatitis. The Company’s two ready-to-use pre-filled syringe (PFS) product candidates include Fedsyra and phenylephrine.
Follow-Up Questions
Qui est le CEO de Talphera Inc ?
Mr. Vincent Angotti est le Chief Executive Officer de Talphera Inc, il a rejoint l'entreprise depuis 2017.
Quelle est la performance du prix de l'action TLPH ?
Le prix actuel de TLPH est de $0.865, il a increased de 1.76% lors de la dernière journée de trading.
Quels sont les thèmes d'affaires principaux ou les industries de Talphera Inc ?
Talphera Inc appartient à l'industrie Pharmaceuticals et le secteur est Health Care
Quelle est la capitalisation boursière de Talphera Inc ?
La capitalisation boursière actuelle de Talphera Inc est de $39.4M
Est-ce que Talphera Inc est un achat, une vente ou un maintien ?
Selon les analystes de Wall Street, 5 analystes ont établi des notations d'analystes pour Talphera Inc, y compris 2 achat fort, 6 achat, 1 maintien, 0 vente et 2 vente forte
